Ziprasidone

Generic Name
Ziprasidone
Brand Names
Geodon, Zeldox
Drug Type
Small Molecule
Chemical Formula
C21H21ClN4OS
CAS Number
146939-27-7
Unique Ingredient Identifier
6UKA5VEJ6X
Background

Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been ...

Indication

In its oral form, ziprasidone is approved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder. The injectable formulation is approved only for treatment of acute agitation in schizophre...

Associated Conditions
Acute Agitation, Agitation, Bipolar 1 Disorder, Psychosis, Schizophrenia, Treatment Resistant Major Depressive Disorder, Acute Manic episode, Acute Mixed manic depressive episode
Associated Therapies
-
Clinical Trials
Related News

Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting

First Posted Date
2009-07-03
Last Posted Date
2010-05-25
Lead Sponsor
University of Bergen
Target Recruit Count
226
Registration Number
NCT00932529
Locations
🇳🇴

Haukeland University Hospital, Division of Psychiatry, Bergen, Sandviken, Norway

Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

Not Applicable
Completed
Conditions
Hyperglycemia
Hyperlipidemia
Interventions
Drug: Olanzapine
Drug: Ziprasidone
First Posted Date
2009-06-01
Last Posted Date
2018-07-18
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
46
Registration Number
NCT00910988
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: B16 Fed
Drug: B16 Fasted
Drug: ziprasidone
First Posted Date
2009-01-13
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
11
Registration Number
NCT00821444
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

Ziprasidone vs Standard Therapy for Agitated Patients in the ED

First Posted Date
2008-11-06
Last Posted Date
2017-09-25
Lead Sponsor
George Washington University
Registration Number
NCT00786318
Locations
🇺🇸

The George Washington University Medical Center, Dept of Emergency Medicine, Washington, D.C., District of Columbia, United States

A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders

First Posted Date
2008-04-02
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
63
Registration Number
NCT00650611
Locations
🇺🇸

Pfizer Investigational Site, Kirkland, Washington, United States

A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: Clozapine
Drug: Ziprasidone
First Posted Date
2008-04-01
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
147
Registration Number
NCT00649844
Locations

Pfizer Investigational Site

A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

Phase 4
Completed
Conditions
Schizophrenia
Schizoaffective Disorder
Interventions
Drug: Ziprasidone
First Posted Date
2008-04-01
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
28
Registration Number
NCT00650429
Locations
🇲🇽

Pfizer Investigational Site, Mexico D F, Mexico

A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs

Phase 4
Completed
Conditions
Schizophrenia
Schizoaffective Disorder
Interventions
Drug: Ziprasidone
First Posted Date
2008-04-01
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
46
Registration Number
NCT00649064
Locations
🇨🇳

Pfizer Investigational Site, Taipei, Taiwan

A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study

Phase 4
Completed
Conditions
Pyschotic Disorders
Interventions
Drug: Ziprasidone
First Posted Date
2008-03-27
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
75
Registration Number
NCT00645320
Locations
🇧🇷

Pfizer Investigational Site, RIO DE Janeiro RJ, Brazil

A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis

First Posted Date
2008-03-27
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
89
Registration Number
NCT00644800
Locations
🇧🇷

Pfizer Investigational Site, Sao Paulo, SP, Brazil

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy